To understand the clinical meaning of MMR deficiency in breast cancer, we assessed a large breast cancer tissue microarray series linked to detailed biomarker and long-term outcome data for immunohistochemically determined loss of MSH2, MSH6, MLH1 or PMS2. Here, MSH2 is linked to hyperinsulinemic hypoglycemia, familial, 4.